Accenture (ACN) said Thursday it has invested in healthcare technology firm Ryght AI, aiming to combine agentic AI with enterprise technology to accelerate drug development.
Terms of the investment were not disclosed.
Accenture said the investment will help life science companies improve clinical trials, specifically trial feasibility, site selection, and patient recruitment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments